References

  1. Rodriguez-Galindo C, Krailo MD, Krasin MJ, et al. Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children’s Oncology Group ARAR0331 Study [published correction appears in J Clin Oncol. 2021 May 10;39(14):1602]. J Clin Oncol. 2019;37(35):3369-3376. doi:10.1200/JCO.19.01276
  2. Jouin A, Helfre S, Bolle S, et al. Adapted strategy to tumor response in childhood nasopharyngeal carcinoma: the French experience. Auf die Tumorreaktion angepasste Behandlungsstrategie beim Nasopharynxkarzinom in der Kindheit: Erfahrungen aus Frankreich. Strahlenther Onkol. 2019;195(6):504-516. doi:10.1007/s00066-019-01461-6
  3. Buehrlen M, Zwaan CM, Granzen B, et al. Multimodal treatment, including interferon beta, of nasopharyngeal carcinoma in children and young adults: preliminary results from the prospective, multicenter study NPC-2003-GPOH/DCOG. Cancer. 2012;118(19):4892-4900. doi:10.1002/cncr.27395
  4. Uezono H, Indelicato DJ, Rotondo RL, et al. Proton therapy following induction chemotherapy for pediatric and adolescent nasopharyngeal carcinoma. Pediatr Blood Cancer. 2019;66(12):e27990. doi:10.1002/pbc.27990
  5. Leung SF, Zee B, Ma BB, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol. 2006;24(34):5414-5418. doi:10.1200/JCO.2006.07.7982
  6. Fang W, Yang Y, Ma Y, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 2018;19(10):1338-1350. doi:10.1016/S1470-2045(18)30495-9